The impact of mismatch repair (MMR), p53, and LCAM-1 immunohistochemical expression on prognosis in low-risk endometrial cancer
, 2, 1, 2
Abstract
Objectives: To investigate the relationship between mismatch repair (MMR) deficiency, TP53, and L1 cell adhesion molecule (L1CAM) immunohistochemical staining and their impact on progression-free survival (PFS) and overall survival (OS) in low-risk endometrial cancer.
Material and methods: A total of 253 low-risk endometrial cancer patients were retrospectively screened. Immunohistochemical stains were applied to tumor tissue samples to assess MMR deficiency, TP53, and L1CAM expression, and survival analysis were performed.
Results: The expected PFS time was 78.6 months for the MMR-proficient group and 70.3 months for the MMR-deficient group (p = 0.011). OS was 71.6 months for the MMR-proficient group and 68.2 months for the MMR-deficient group (p = 0.755). L1CAM overexpression was associated with a poorer PFS, 62.7 months compared to 77.7 months (p = 0.039). However, there was no statistically significant difference in OS, 58.5 months versus 72.1 months, respectively (p = 0.242). p53 abnormal (p53-abn) staining was associated with a worse prognosis in terms of PFS, 62.8 months versus 77.7 months (p = 0.035), and OS, 43.4 months versus 73 months, respectively (p < 0.001), compared to patients with wild-type staining.
No significant statistical relationship was observed in survival times concerning tumor diameter, grade, and lymphadenectomy status. In a multivariate analysis, MMR deficiency emerged as an independent poor prognostic factor for PFS, while p53-abn was identified as an independent poor prognostic factor for OS.
Conclusions: p53-abn staining was associated with a poor prognosis for both PFS and OS in low-risk endometrial cancer patients. Meanwhile, MMR deficiency and L1CAM positivity were found to be associated solely with a poorer prognosis for PFS.
Keywords: low-risk endometrial cancermismatch repairTP53L1CAM
References
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1): 12–39.
- Xu Y, Burmeister C, Hanna RK, et al. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer. 2016; 26(6): 1137–1142.
- Bednarikova M, Vinklerova P, Gottwaldova J, et al. The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer. J Clin Med. 2021; 10(12): 2640.
- Topfedaisi Ozkan N, Meydanlı MM, Sarı ME, et al. Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone. J Gynecol Oncol. 2017; 28(5): e65.
- Francis SR, Ager BJ, Do OA, et al. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019; 154(1): 38–44.
- Kandoth C, Schultz N, Cherniack AD, et al. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67–73.
- Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2): 299–310.
- Perri F, Pisconti S, Della Vittoria Scarpati G. P53 mutations and cancer: a tight linkage. Ann Transl Med. 2016; 4(24): 522.
- Li GM. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008; 18(1): 85–98.
- Bosse T, Nout RA, Stelloo E, et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. Eur J Cancer. 2014; 50(15): 2602–2610.
- Dellinger TH, Smith DD, Ouyang C, et al. L1CAM is an independent predictor of poor survival in endometrial cancer — An analysis of The Cancer Genome Atlas (TCGA). Gynecol Oncol. 2016; 141(2): 336–340.
- Zeimet AG, Reimer D, Huszar M, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst. 2013; 105(15): 1142–1150.
- van der Putten LJM, Visser NCM, van de Vijver K, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016; 115(6): 716–724.
- Reijnen C, Gogou E, Visser NCM, et al. ENITEC Consortium. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Med. 2020; 17(5): e1003111.
- León-Castillo A, de Boer SM, Powell ME, et al. TransPORTEC consortium. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol. 2020; 38(29): 3388–3397.
- Le D, Uram J, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372(26): 2509–2520.
- Kim SR, Pina A, Albert A, et al. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. Int J Gynecol Cancer. 2020; 30(6): 783–788.
- McMeekin DS, Tritchler DL, Cohn DE, et al. Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study. J Clin Oncol. 2016; 34(25): 3062–3068.
- Stasenko M, Feit N, Lee SSK, et al. Clinical patterns and genomic profiling of recurrent 'ultra-low risk' endometrial cancer. Int J Gynecol Cancer. 2020; 30(6): 717–723.
- Moroney MR, Davies KD, Wilberger AC, et al. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019; 153(3): 517–520.
- Gezer Ş, Bayrak BY. Metastatic and synchronous ovarian involvement in low-risk endometrial cancer; clinicopathological analysis with detection of DNA mismatch repair deficiency. Ginekol Pol. 2021; 92(9): 599–606.
- Vrede SW, van Weelden WJ, Visser NCM, et al. ENITEC Consortium. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer. Gynecol Oncol. 2021; 161(3): 787–794.
- Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123(5): 802–813.
- Kommoss F, Kommoss F, Grevenkamp F, et al. L1CAM: amending the "low-risk" category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017; 143(2): 255–262.
- Giannini A, D'Oria O, Corrado G, et al. The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2024; 309(3): 789–799.
- Ureyen I, Karalok A, Turkmen O, et al. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: what is the importance of LVSI? Arch Gynecol Obstet. 2020; 301(3): 737–744.
- Ayhan A, Şahin H, Sari ME, et al. Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer. Int J Gynecol Cancer. 2019; 29(3): 505–512.
